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Acute gastrointestinal bleeding from a 
chronic cause: a teaching case report 
Michaël R. Laurent¹*, Lode Van Overbeke² 
Abstract 
Gastrointestinal bleeding  (GI bleed) is a common and potentially life-threatening reason for emergency room and 
intensive care unit admission. This article reports the case of an 83-year-old man with acute GI bleeding from an 
unusual cause. The clinical information is presented in a step-by-step and question-answer format for learning 





In March 2011, an 83-year-old man developed paroxys-
mal atrial fibrillation and distal right leg ischaemia suc-
cessfully treated with embolectomy. He had a remote 
medical history of hypersensitivity pneumonitis (from 
mushroom farming), coronary artery bypass grafting 
(CABG) surgery, chronic lymphocytic leukaemia (CLL), 
and Billroth type II gastrectomy for previous gastric ul-
cer bleeding. 
His medication included a β-blocker, a statin, low-dose 
aspirin, an angiotensin II receptor blocker and a proton-
pump inhibitor (PPI). 
Lab results were normal except for slight thrombocyto-
penia (141,000 platelets/µL; normal range 150,000-
450,000 platelets/µL) and lymphocytosis (21,675 
cells/µL, normal range 1,200-3,600 cells/µL with 
smudge cells, monoclonal B-lymphocytes 17,700 
cells/µL). 
Echocardiography showed only left atrial dilatation and 
grade 2 mitral insufficiency, without inferior vena cava 
dilatation. 
He lived independently and was in an excellent general  
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Question set 1 
1. Which risk factors for bleeding does this patient 
have? 
2. Which anticoagulation strategy would you rec-
ommend? 
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Long answers 
The new diagnosis of non-valvular atrial fibrillation with 
peripheral embolism is a clear indication for oral antico-
agulation. The CHA2DS2-VASc score (Table 1) may be 
useful to determine which individuals would benefit 
from oral anticoagulation: this patient’s age ≥75 years 
(two points), thromboembolism (two points) and his-
tory of vascular disease (total score 5) clearly put him in 
a high risk category for recurrent venous thromboem-
bolic (VTE) complications (7.2% per year risk of VTE[1]). 
This patient's risk of VTE should be weighed against the 
risk of bleeding, which is also elevated in this patient. 
Recommended strategies for the prevention of GI 
bleeding include PPIs and Helicobacter pylori eradica-
tion -if required- prior to starting oral anticoagulants. 
Vitamin K-antagonists such as warfarin are first line an-
ticoagulants; novel oral anticoagulants (NOACs) may 
also be appropriate in this patient because they have 
been associated with lower bleeding risks (but these 
were not yet available in 2011). Aspirin has only weak 
preventive effects against VTE and is not recom-
mended for this purpose. 
The prior history of CABG is a clear indication for low-
dose aspirin. However, the combination of warfarin and 
aspirin increases the risk of bleeding and has not been 
shown to decrease the risk of cardiovascular events 
compared to warfarin alone.[2][3] Whether the combina-
tion of NOACs with aspirin or dual anti-platelet therapy 
is safe and effective requires further study. 
 
 
Case continued (part 2) 
Gastroscopy and biopsies showed an inflammatory 
pseudopolyp at the gastro-jejunal suture line of the pre-
vious Billroth surgery, and hyperaemic gastric mucosa 
with negative immunohistochemistry for Helicobacter 
pylori. Subsequently, a vitamin K-antagonist was added 
to prevent recurrent thromboembolic events. Despite 
the above-mentioned evidence-based recommenda-
tions, low-dose aspirin was continued after discussion 
with the patient and his cardiologist. 
One week later, while INR was 2.5 (target 2.0 - 3.0 ther-
apeutic range for vitamin K-antagonists), he was 
brought by ambulance to the emergency room because 
of blood vomiting (haematemesis) and passage of dark 
stool (melena). The patient denied drinking alcohol or 
taking non-steroid anti-inflammatory drugs. 
Blood pressure was low (86/44 mmHg), pulse irregular 
88/minute, temperature 36.5°C (orally) and oxygen sat-
uration 97% while breathing room air. There were no 
clinical signs of cirrhosis. 
Liver tests and ferritin serum concentrations were nor-
mal. 
An emergency upper endoscopy showed massive blood 





Table 1 | CHA2DS2-VASc score 
 Condition Points 
 C  Congestive heart failure (or Left ventricular systolic dys-
function) 
1 
 H Hypertension: blood pressure consistently above 140/90 
mmHg (or treated hypertension on medication) 
1 
 A2 Age ≥75 years 2 
 D Diabetes Mellitus 1 
 S2 Prior Stroke or Transient ischemic attack or thromboem-
bolism  
2 
 V Vascular disease (e.g. peripheral artery disease, myocar-
dial infarction, aortic plaque) 
1 
 A Age 65–74 years 1 
 Sc Sex category (i.e. female sex) 1 
Short answer set 1 
1. Which risk factors for bleeding does this patient 
have?  
His older age (≥75 years), low-dose aspirin 
treatment and prior gastric ulcer bleeding 
with Billroth II gastrectomy. 
2. Which anticoagulation strategy would you rec-
ommend? 
Continuation of his PPI and an upper GI en-
doscopy (with Helicobacter pylori eradica-
tion if required) prior to initiating an oral an-
ticoagulant instead of low-dose aspirin.  
Question set 2 
1. What would be the appropriate next steps in the 
management of this patient? 
2. What single tests or examination would be the 
most useful step to determine the cause of this 
patients bleeding? 
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Long answers 
Management of serious GI bleeding involves place-
ment of 1-2 large-bore i.v. lines, volume resuscitation 
with crystalloids and red blood cell transfusions, cor-
rection of INR, and admission to the intensive care 
unit. 
INR can be corrected quickly with fresh frozen plasma 
or coagulation factor concentrate; the latter is more 
expensive but may have advantages when administra-
tion of large volumes of i.v. fluid is not desired. Vitamin 
K should also be given to antagonize the effect of war-
farin in the coming days, but this does not reverse the 
effect of vitamin K antagonists immediately. 
PPIs are usually started empirically and continued until 
the source of bleeding is identified. 
Red blood cell transfusions are usually given to main-
tain haemoglobin > 7 g/dL, but in this patient with prior 
history of CABG, a threshold of 8 g/dL may be consid-
ered.[4] 
The platelet count in this patient was only very mildly 
lowered, which in itself is not expected to pose an in-
creased risk of bleeding. However his low-dose aspirin 
treatment impairs platelet function, which can be cor-
rected with platelet transfusions. 
The clinical presentation with haematemesis is sugges-
tive of a bleeding source proximal to the ligament of 
Treitz. Emergency upper endoscopy may be false-neg-
ative e.g. because the patient is hypotensive and 
bleeding stops, or because the bleeding source is ob-
scured by massive blood; prokinetics could have been 
given before emergency endoscopy to enhance visuali-
zation. Patients without haematemesis may be investi-
gated by colonoscopy or transvenous angiography for 
identification and source control of acute GI bleeding. 
 
Case continued (part 3) 
The patient was given crystalloids for volume resuscita-
tion and admitted to the intensive care unit for red 
blood cell transfusion, immediate correction of coagu-
lation with transfusion of platelets and fresh frozen 
plasma, and PPIs. His aspirin and vitamin K antagonist 
were discontinued and vitamin K was administered 
prophylactically to maintain reversal of his oral antico-
agulant. 
Repeat endoscopy the next day revealed oozing from 
fundal and oesophageal varices. The oesophageal vari-
ces were treated with ligation, and the patient became 
haemodynamically stable and required no more trans-
fusions. A somatostatin drip and prophylactic ceftriax-
one were administered. 
Hepatitis B and C virus serology, antinuclear-, anti-
smooth muscle- and anti-mitochondrial antibodies, α1-
antitrypsin and ceruloplasmin were normal. Ultraso-
nography and computed tomography of the abdomen 
and magnetic resonance cholangiopancreatography 
showed emboligenic right kidney infarction but a nor-







Short answer set 2 
1. What would be the appropriate next steps in the 
management of this patient? 
Placement of 1-2 large-bore intravenous 
lines, volume resuscitation with crystalloids, 
transfusion of red blood cells and platelets, 
correction of INR, i.v. administration of PPIs, 
and admission to the intensive care unit. 
2. What single tests or examination would be most 
useful to determine the cause of this patients 
bleeding? 
Repeat endoscopy after resuscitation. 
Question set 3 
1. What would be the most appropriate next inves-
tigation to determine the cause of this patient’s 
oesophageal varices? 
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Long answer 
Oesophageal varices are almost always due to cirrho-
sis. In this case however, biochemical and imaging 
findings do not indicate cirrhosis, suggesting non-cir-
rhotic portal hypertension. A liver biopsy can defini-
tively exclude cirrhosis. When performed via the 
transjugular route, the portosystemic venous pressure 
gradient can be measured during the same session to 
confirm portal hypertension and whether or not it re-
sults from presinusoidal, sinusoidal or a post-sinusoidal 
cause.[5] 
Case continued (part 4) 
On transjugular catheterization, the hepatic venous 
pressure gradient was 17 mmHg (normal values <6 
mmHg), and biopsy showed engorged sinusoids and 
signs of portal hypertension with normal parenchyma. 
Propranolol and enoxaparin were initiated. On two an-
nual follow-up endoscopies, grade I varices were noted 
which required no further ligations. 
Discussion 
Variceal bleeding should be considered in the differen-
tial diagnosis of otherwise unexplained acute upper 
gastrointestinal bleeding, even in the absence of clinical 
or biochemical signs of cirrhosis. Insufflation can ob-
scure moderate varices at initial or previous endosco-
pies, as can hypotension during haemorrhagic shock. 
Portal hypertension is assessed by the hepatic venous 
pressure gradient (HVPG). An HVPG of 1 to 5 mmHg is 
normal. Portal hypertension is defined as HVPG ≥ 6 
mmHg, but this usually only becomes clinically signifi-
cant ≥ 10 mmHg when varices start developing. From 
12 mmHg HVPG, ascites may develop and there ap-
pears to be a risk of variceal bleeding, while from 16 
mmHg a risk of hepatic decompensation and mortality 
has been noted.[5] Other non-invasive measurements 
may qualitatively suggest portal hypertension e.g. por-
tal vein duplex and ultrasound assessment of portal vein 
diameter, although formal quantification relies on inva-
sive HVPG measurement. 
Management of variceal bleeding 
Haemodynamic resuscitation, correction of coagula-
tion abnormalities, airway protection in case of active 
haematemesis, infection control (prophylactic quino-
lone or third-generation cephalosporin) and achieving 
haemostasis are the cornerstone of variceal bleeding 
management.[6] 
The first step is to initiate pharmacological therapy to 
reduce portal venous pressure, usu-
ally terlipressin (a vasopressin analogue) 
or octreotide (a somatostatin analogue). As a group, 
these drugs reduce mortality, improve haemostasis and 
shortened duration of hospitalisation in patients with 
variceal bleeding but only terlipressin individually has 
demonstrated significant survival benefit.[7][8] Pharma-
cotherapy should be started early when variceal bleed-
ing is suspected and should not be delayed until after 
endoscopic confirmation of the diagnosis of variceal 
bleeding. In our patient we used short-acting somato-
statin in a continuous infusion due to availability in our 
hospital at that time. 
Gastro-oesophageal endoscopy can confirm the diag-
nosis and allow haemostasis. Variceal ligation (banding 
of the varices) is the standard of care but sclerotherapy 
(injection of foam to occlude blood flow within the var-
ices) is an alternative, which may be useful for gastric 
varices.[9][6] Balloon tamponade e.g. using 
the Sengstaken-Blakemore balloon can allow tempo-
rary or salvage bleeding control, but there are several 
possible complications and a high risk of rebleeding af-
ter balloon deflation.[6] Transjugular intrahepatic porto-
systemic shunt (TIPS) placement or surgery are effec-
tive second-line therapies after failure of endoscopic 
haemostasis, but surgery carries a far greater mortality 
risk.[10] Even if initial endoscopy successfully stops the 
variceal bleeding, early TIPS should be considered in 
patients at high risk of treatment failure.[11] 
For further details, we refer to several recent interna-
tional recommendations for the management of vari-
ceal bleeding.[6][12][13] 
Noncirrhotic portal hypertension 
Noncirrhotic portal hypertension can result from prehe-
patic, posthepatic (inferior vena cava obstruction or 
cardiac disease) or intrahepatic causes.[14] Hepatic 
causes can be further subdivided into presinusoidal, si-
nusoidal or postsinusoidal causes (Table 2). 
Short answer set 3 
1. What would be the most appropriate next inves-
tigation to determine the cause of this patient’s 
oesophageal varices? 
A transjugular liver biopsy and measurement 
of the portosystemic venous pressure gradi-
ent. 
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Table 2 | Conditions associated with non-cirrhotic portal hy-
pertension 
Proposed criteria for idiopathic noncirrhotic portal hy-
pertension include the absence of the aforementioned 
conditions or other causes of chronic liver diseases, cir-
rhosis on biopsy, or portal or hepatic vein throm-
bosis.[14] 
Variceal haemorrhage and ascites are the commonest 
presentations, and underlying disorders or the develop-
ment of complications including ascites, bleeding 
or portal vein thrombosis may negatively affect sur-
vival.[15][16] 
Chronic lymphocytic leukaemia (CLL) is not uncommon 
in elderly subjects and does not require specific therapy 
unless it causes symptoms e.g. from secondary cytope-
nia, B symptoms, splenomegaly or when there is a rapid 
increase in lymphocyte counts. CLL has been associ-
ated with idiopathic non-cirrhotic portal hypertension, 
ascites and hepatorenal syndrome although the inci-
dence of portal hypertension in patients with CLL as 
well as any causal relationship or the benefit of haema-
tological treatment remains uncertain.[14][17][18] 
Different pathophysiological factors have been sug-
gested including lymphocytic hepatosplenic infiltration 
(which was absent in this case), increased spleno-portal 
blood flow, thrombosis of terminal portal vein 
branches, reactive fibrosis, nodular regenerative hyper-
plasia or veno-occlusive disease.[14][17][18] Splenectomy 
may ameliorate portal hypertension in cases with in-
creased splenic blood flow. Anticoagulation has been 
proposed by some and is recommended in cases of por-
tal vein thrombosis or underlying thrombophilia, but 
may increase the risk of bleeding. 
Our case report reminds physicians to consider the pos-
sibility of portal hypertension or its complications (in-
cluding variceal bleeding, ascites or otherwise unex-
plained thrombocytopenia) in patients with suggestive 
symptoms even if they do not have cirrhosis, especially 
in the presence of potential causes of non-cirrhotic por-
tal hypertension. 
Final diagnosis 
Variceal bleeding due to idiopathic non-cirrhotic portal 
hypertension, possibly associated with chronic lympho-
cytic leukemia. 
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 Conditions associated with non-cirrhotic portal hypertension 
Prehepatic causes Portal or splenic vein thrombosis 
 Arteriovenous fistula 
 Splenomegaly (due to increased portal blood flow) 
Hepatic causes Primary biliary cirrhosis 
 Primary sclerosing cholangitis 
 Chronic pancreatitis 
 Hereditary haemorrhagic telangiectasia 
 Schistosomiasis 
 Congenital hepatic fibrosis 
 Nodular regenerative hyperplasia 
 Fibrosis of space of Disse 
 Granulomatous or infiltrative liver diseases (Gaucher's disease, mucopolysaccharidosis, sarcoidosis, 
lymphoproliferative malignancies, amyloid deposition, …) 
 Toxicity (from arsenic, copper, vinyl chloride monomers, mineral oil, vitamin 
A, azathioprine, dacarbazine, methotrexate, amiodarone, …) 
 Viral hepatitis 
 Fatty liver disease 
 Veno-occlusive disease 
 Budd-Chiari syndrome 
Posthepatic causes Inferior vena cava obstruction 
 (Right-sided) heart failure 
 Hepatic vein thrombosis 
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